Lupin Limited is a multinational pharmaceutical company specializing in branded and generic formulations, biotechnology products, active pharmaceutical ingredients, and complex specialty medicines. Established in 1968 by Dr. Desh Bandhu Gupta, the company has grown into one of India’s leading pharmaceutical manufacturers with operations across more than 100 countries. Lupin maintains a strong presence in cardiovascular, diabetes, respiratory, anti-infective, gastrointestinal, women’s health, and pediatric therapies while expanding into biosimilars and specialty pharmaceuticals. The company operates advanced manufacturing facilities and research centers that comply with global regulatory requirements, supporting exports to major international markets including the United States, Europe, Japan, and Australia. Lupin’s continued investment in innovation, complex generics, and sustainable healthcare solutions has strengthened its competitive position globally. With a patient-focused strategy and extensive product portfolio, the company remains committed to improving healthcare outcomes through high-quality, affordable medicines and scientific excellence.
NSE: LUPIN | BSE: 500257
Mumbai, Maharashtra, India
